909253-26-5

Basic information

• Product Name: 4-(4-methylpiperazin-1-yl)benzamide
• Synonyms: 4-(4-methylpiperazin-1-yl)benzamide
• CAS NO: 909253-26-5
• Molecular Weight: 219.286
• Mol File: 909253-26-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(4-methylpiperazin-1-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-methylpiperazin-1-yl)benzamide(909253-26-5)
• EPA Substance Registry System: 4-(4-methylpiperazin-1-yl)benzamide(909253-26-5)

Safety Data

• Hazardous Substances Data: 909253-26-5(Hazardous Substances Data)

Upstream product

• 34334-28-6 4-(4-methylpiperazin-1-yl)benzonitrile 
• 773137-71-6 ethyl 4-(4-methylpiperazin-1-yl)benzoate 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 354813-15-3 4-(4-methylpiperazin-1-yI)benzoic acid 
• 354813-14-2 4-(4-methylpiperazin-1-yl)benzoic acid methyl ester 
• 109-01-3 1-methyl-piperazine 
• 403-33-8 methyl 4-flurobenzoate 

Downstream Products

• 909253-24-3 ethyl 1-(1-ethoxyethyl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylate 
• 909253-25-4 C₂₉H₃₄ClN₇O₃S 
• 909253-23-2 N-{5-[N'-(4-chlorophenyl)-N'-methylhydrazinocarbonyl]-1H-thieno[2,3-c]pyrazol-3-yl}-4-(4-methylpiperazin-1-yl)benzamide 

Relevant articles and documents

Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors

Starting from the phase II clinical FGFR inhibitor lucitanib (2), we conducted a medicinal chemistry approach by opening the central quinoline skeleton coupled with a scaffold hopping process thus leading to a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives. Compound 25a was identified to show selective and equally high potency against FGFR1/2 and VEGFR2 with IC50 values less than 5.0 nM. Significant antiproliferative effects on both FGFR1/2 and VEGFR2 aberrant cancer cells were observed. In the SNU-16 xenograft model, compound 25a showed tumor growth inhibition rates of 25.0% and 81.0% at doses of 10 mg/kg and 50 mg/kg, respectively, with 5% and 10%body weight loss. In view of the synergistic potential of FGFs and VEGFs in tumor angiogenesis observed in preclinical studies, the FGFR/VEGFR2 dual inhibitor 25a may achieve better clinical benefits.

Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof

The present invention concerns hydrazinocarbonyl-thieno[2,3-c]pyrazoles of formula (I): wherein R1, R3, R4, are R5 are as defined in the disclosure; their preparation method, compositions containing the same and their use for the treatment of pathological conditions, in particular as anticancer agents.